Adagrasib for KRAS-Mutated Lung Cancer

This trial tests a new treatment called adagrasib (also known as Krazati or MRTX-849) for individuals with a specific type of lung cancer that has a KRAS G12C mutation. Researchers aim to evaluate the effectiveness of two different doses for treating this cancer. The trial seeks participants whose cancer has spread and who have already undergone chemotherapy and immune checkpoint inhibitors. It is not suitable for those who have previously received a KRAS G12C targeted treatment or have certain untreated brain conditions. Participants must have recovered from their previous cancer treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you must stop taking your current medications. However, if you have certain medical conditions or need to take certain medications that could make it unsafe, a trial doctor might advise changes.

Research has shown that adagrasib is generally safe for people with KRAS-mutated non-small-cell lung cancer (NSCLC). In earlier studies, patients who took adagrasib did not experience unexpected or dangerous side effects.

Studies have found that adagrasib is well-tolerated, with most side effects being mild and manageable. This is important because it allows most people to continue treatment without serious problems.

Adagrasib has been used in patients before and demonstrated benefits without causing new safety issues. This supports the idea that the treatment is safe for people with this specific type of lung cancer.

Researchers are excited about Adagrasib for KRAS-mutated lung cancer because it targets a specific mutation in the KRAS gene, which is a common driver of cancer cell growth. Unlike standard treatments like chemotherapy, which attack rapidly dividing cells in general, Adagrasib specifically inhibits the KRAS G12C mutation, potentially leading to more effective and targeted therapy with fewer side effects. Additionally, Adagrasib is available in two formulations: one taken without regard to food at 600mg twice daily, and another taken with food at 400mg twice daily, offering flexibility in dosing that can improve patient convenience and adherence.

In previous studies, adagrasib has shown promising results for treating KRAS G12C-mutated non-small cell lung cancer (NSCLC). Research indicates that patients taking adagrasib experienced longer periods without cancer progression, known as improved progression-free survival. One study showed that adagrasib delayed cancer progression more effectively than the usual treatment, docetaxel. This trial will test different dosages of adagrasib, specifically 600mg BID and 400mg BID. Additionally, another study found that combining adagrasib with pembrolizumab, a drug that boosts the immune system, further improved survival rates. These findings suggest that adagrasib could be a strong option for people with this specific type of lung cancer.¹⁴⁶⁷⁸